7 Talos offers an AI‑driven microfluidic platform that automates and optimizes CAR‑T cell manufacturing. By integrating organ‑on‑chip bioreactors with real‑time image analysis, reinforcement‑learning control, and multi‑omics data, the system delivers standardized, cost‑effective, and personalized CAR‑T products for biopharma and research labs.
Funding
Funding not disclosed
Founders
Product
Problem
CAR‑T cell therapies are limited by complex, time‑consuming manufacturing processes and a lack of real‑time monitoring, which leads to high costs, variable product quality, and delayed treatment adjustments for patients.
Solution
7Talos provides an AI‑driven, microfluidic platform that automates and optimizes the growth and engineering of CAR‑T cells. Integrated organ‑on‑chip bioreactors continuously culture T cells while high‑resolution image analysis quantifies cell occupancy and health. Reinforcement‑learning algorithms create a self‑regulating feedback loop that adjusts culture conditions in real time, improving cell viability and potency. The system delivers standardized, cost‑effective CAR‑T products that can be personalized to individual patients, enabling faster, more reliable therapy deployment.
Target Audience
Primary customers are biopharmaceutical companies and academic cell‑therapy labs developing autologous CAR‑T treatments, as well as contract manufacturing organizations seeking to streamline and personalize their production pipelines.
Features
- Automated microfluidic bioreactor for scalable T‑cell culture and CAR‑T manufacturing
- Real‑time image recognition and AI analysis of cell growth dynamics and occupancy
- Reinforcement‑learning control loop that continuously optimizes culture parameters
- Integrated multi‑omics data capture for comprehensive cell quality assessment
- Robotics‑enabled handling to reduce manual intervention and contamination risk
- Decentralized platform architecture that supports distributed production sites and rapid scaling